CRISPR Therapeutics AG

NASDAQ:CRSP

Biotechnology

Healthcare
$40.19 +2.70%

+$1.43 today

Market cap
$3.90B
Beta
1.70
P/E (TTM)
-9.2
EPS (TTM)
-$5.92
52W Low $43.23High $78.48

Volume 3.97M

Average 1.70M

CRSP Total Non-current Assets

All assets not expected to be converted to cash within one year.

CRISPR Therapeutics AGNASDAQ: CRSP

Total Non-current Assets · Q3 FY2026 · quarter ended Sep 2026

Total non-current assets falls 14.2% from a year ago

Total non-current assets stood at $271.33M at the end of Q3 FY2026, down 14.2% from a year earlier and down 2.7% from the prior quarter. Over 3 fiscal years it compounded at -10.5% a year.

Context

  • Total non-current assets amounted to 10.6% of total assets at the end of Q3 FY2026, down 3.5 pp from a year earlier.
  • Total non-current assets increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether total non-current assets keeps falling in the next quarterly balance sheet after a -14.2% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterSep 2026
$271.33M-2.7% QoQ
Last fiscal yearDec 2025
$279.57M-8.3% YoY
Year agoSep 2025
$316.22M-14.2% since
Total Non-current Assets past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-14.2%——
1 year-8.3%——
3-year CAGR-10.5%——
5-year CAGR——
10-year CAGR——

Total Non-current Assets history

USD · from the balance sheet

Latest · FY2025
279.57M USD
Year-over-year change
-8.3%
4-year CAGR
-4.4%

Total Non-current Assets vs competitors

How CRSP compares with its peers on the latest reported figures

  • CRSP's Sep 2026 total non-current assets of $271.33M is the 3rd highest of the 7 companies compared; the peer median is $181.57M.
  • Its year-over-year change of -14.2% is the 3rd highest of 7, against a peer median of -15.7%.
  • Total non-current assets amounts to 10.6% of total assets for CRSP, versus a peer median of 31.5%.
CRSP Competitors Peer median
Total Non-current Assets for CRSP and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
DNAGinkgo Bioworks Holdings, Inc.Mar 2026$623.12M -14.5%-15.9%60.3%
NTLAIntellia Therapeutics, Inc.Mar 2026$292.33M -32.8%+1.2%38.5%
CRSPCRISPR Therapeutics AGSep 2026$271.33M -14.2%-10.5%10.6%
BEAMBeam Therapeutics Inc.Jun 2026$207.76M -3.7%-5.1%15.0%
RGNXREGENXBIO Inc.Mar 2026$155.38M -12.6%-25.6%45.4%
DTILPrecision BioSciences, Inc.Mar 2026$35.2M -16.8%-3.0%24.5%
EDITEditas Medicine, Inc.Mar 2026$21.27M -45.2%-47.6%14.2%
Peer median (excluding CRSP) $181.57M-15.7%-10.5%31.5%

Competitors are the stored peer set for CRSP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents923.03M211.89M389.48M298.26M355.19M
Short-term Investments1.46B1.6B1.3B1.61B1.63B
Net Receivables305K0200M25M0
Inventory00000
Other Current Assets8.4M11.7M6.5M8.31M9.84M
Total Current Assets2.42B1.85B1.91B1.94B1.99B
Property, Plant & Equipment (Net)312.04M320.56M305.94M277.55M247.58M
Goodwill00000
Intangible Assets125K71K16K00
Long-term Investments053.13M1.97M00
Tax Assets00000
Other Non-current Assets22.2M16.28M13.57M27.35M32M
Total Non-current Assets334.36M390.03M321.49M304.9M279.57M
Total Assets2.75B2.24B2.23B2.24B2.27B
Account Payables14.82M27.43M38.15M14.71M11.14M
Short-term Debt12.16M15.84M15.63M17.29M18.58M
Tax Payables000451K0
Deferred Revenue1.01M04.11M3.85M15.77M
Other Current Liabilities67.51M58.46M33.13M33.05M89.55M
Total Current Liabilities119.88M121.11M108.79M87.78M149.12M
Long-term Debt0000188.17M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)12.32M12.32M14.01M12.32M0
Other Non-current Liabilities7.34M5.97M958K3.44M(182.03M)
Total Non-current Liabilities232.53M246.47M237.98M222.17M194.31M
Total Liabilities352.42M367.58M346.77M309.95M343.43M
Common Stock2.39M2.44M2.5M2.7M3.09M
Retained Earnings(195.92M)(846.09M)(999.7M)(1.37B)(1.95B)
Accumulated OCI(5.07M)(15.65M)1.91M1.84M4.82M
Other Stockholders Equity00100
Minority Interest00000
Total Equity2.4B1.88B1.88B1.93B1.92B
Total Debt225.03M244.02M238.63M223.69M394.91M
Net Debt(698M)32.14M(150.85M)(74.56M)39.73M

CRISPR Therapeutics AG

NASDAQ:CRSP

Intrinsic Alpha fair value

Locked

Current Price

$40.19

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.